Idexx Laboratories (IDXX) Stock Price & Analysis
IDXX Stock Chart & Stats
- Day’s Range
- MXN 10,569.17 - MXN 10,569.17
- 52-Week Range
- MXN 8,247.61 - MXN 14,152.50
- Previous Close
- MXN 10,581.00
- Volume
- 0
- Average Volume (3M)
- 17
- Market Cap
- MXN 816.04B
- Enterprise Value
- MXN 42.65B
- Total Cash (Recent Filing)
- MXN 196.93M
- Total Debt (Recent Filing)
- MXN 1.10B
- Price to Earnings (P/E)
- 38.7
- Beta
- 0.49
- Next Earnings
- Feb 08, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Recurring Diagnostics Growth
Strong recurring diagnostic growth demonstrates durable demand beyond clinic visit volumes and supports predictable revenue from consumables and services. The premium to U.S. visit trends also indicates effective pricing, workflow integration, and customer retention.
High And Expanding Profitability
High margins and continued expansion indicate strong pricing, scale benefits, and cost control across the diagnostic platform. Sustained profitability gives IDEXX resources to fund innovation and commercial investment while preserving meaningful earnings power.
Strong Cash Generation
Robust free cash flow and healthy conversion show that reported earnings are translating into usable cash. This supports ongoing research, product launches, debt management, and shareholder returns without requiring heavy external financing.
Bears Say
U.S. Visit Pressure
Persistent declines in U.S. clinical and wellness visits can constrain test volumes and slow growth in visit-linked services. Continued consumer pressure and slower pet additions may delay volume recovery, even if IDEXX retains share and gains pricing.
Growth Normalization
A more mature growth profile reduces the contribution from pure top-line acceleration and places greater importance on execution, pricing, and innovation. Slower revenue expansion can also limit operating leverage and make future earnings growth less forgiving.
Lean Equity Base Sensitivity
Although leverage is described as manageable, a relatively lean equity base can amplify reported returns and increase sensitivity if profitability weakens. Lower equity cushioning may make earnings volatility more pronounced during a period of slower growth.
IDXX FAQ
What was Idexx Laboratories’s price range in the past 12 months?
What is Idexx Laboratories’s market cap?
When is Idexx Laboratories’s upcoming earnings report date?
How were Idexx Laboratories’s earnings last quarter?
Is Idexx Laboratories overvalued?
Does Idexx Laboratories pay dividends?
What is Idexx Laboratories’s EPS estimate?
How many shares outstanding does Idexx Laboratories have?
What happened to Idexx Laboratories’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Idexx Laboratories?
What is the TipRanks Smart Score and how is it calculated?
Idexx Laboratories Stock Smart Score
Company Description
Idexx Laboratories
IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors. The company organizes its operations across several key divisions: the Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry, and Dairy (LPD), and additional segments. For companion animals, IDEXX offers a comprehensive suite of point-of-care veterinary diagnostic tools, such as instruments, consumables, and rapid assay kits. It also provides reference laboratory diagnostic and consultation services, alongside practice management and diagnostic imaging solutions for veterinarians. Furthermore, the company supports the biomedical research community with health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services. In the livestock, poultry, and dairy markets, IDEXX supplies diagnostic and health-monitoring solutions. Its water testing portfolio includes products designed to detect various microbiological contaminants, notably the Colilert, Colilert-18, and Colisure tests for total coliforms and E. coli, as well as Enterolert, Pseudalert, Filta-Max, Filta-Max xpress, Legiolert, and Quanti-Tray products. Beyond these, IDEXX extends its reach to human point-of-care medical diagnostics, offering electrolyte and blood gas analyzers, and SARS-CoV-2 RT-PCR tests. Other key offerings encompass in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers, as well as SNAP rapid assay test kits. Veterinary software and services for both independent clinics and large corporate veterinary groups are also part of its offerings. The company distributes its extensive product and service catalog through its own dedicated marketing, customer service, sales, and technical service teams, supplemented by independent distributors and other resellers. IDEXX Laboratories, Inc. was established in 1983 and maintains its headquarters in Westbrook, Maine.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Michael Erickson
- Employees
- 11,000
- Website
- www.idexx.com
- Address
- One IDEXX Drive, Westbrook, ME, 04092, US
Idexx Laboratories (IDXX) Earnings & Revenues
IDXX Company Deck
IDXX Earnings Call
Earnings Call SentimentPositive
The call conveyed a strongly constructive operational and financial picture: solid organic revenue growth (~9% Q2), recurring CAG Diagnostics strength, robust margin and EPS expansion, strong free cash flow and aggressive capital returns, plus clear product and innovation momentum (inVue Dx, Cancer Dx, Catalyst SDMA). Offsetting items include continued pressure on U.S. clinic and wellness visits, a Q2 instrument revenue lap effect, foreign-exchange headwinds, and planned incremental investments that will temper near-term margin gains. Overall, the positive drivers — durable recurring revenue expansion, margin gains, cash generation, and multiple innovation milestones — materially outweigh the cited headwinds.
View all MX:IDXX earnings summariesIDXX Net sales Breakdown
- 91.86% CAG
- 4.67% Water
- 3.06% LPD
- 0.41% Other
IDXX Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 4 | 3 |
| Technical Analysis | 4 | 4 | 2 |
| Moving Averages | 11 | 0 | 1 |
